Home・Akciju saraksts・CRISPR Therapeutics AG

CRISPR Therapeutics AG

Atvērts

SektorsVeselības aprūpe

52.85 7.09

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

48.94

Max

52.47

Galvenie mērījumi
By Trading Economics
Ienākumi	7.7M -123M
Pārdošana	594K 1.5M
EPS	-1.28
Peļņas marža	-8,431.481
Darbinieki	393
EBITDA	31M -118M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+50.21% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-315M 4.6B
Iepriekšējā atvēršanas cena	45.76
Iepriekšējā slēgšanas cena	52.85

Ziņu noskaņojums

By Acuity

24%

76%

67 / 340 Rangs Healthcare

CRISPR Therapeutics AG Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. aug. 23:02 UTC

Social Media

News

CRISPR Therapeutics reported second-quarter revenue of $10.18 million, exceeding expectations. Shares are trading higher in after-market hours following the earnings report.

2026. g. 31. jūl. 23:06 UTC

Shares of CRISPR Therapeutics AG are trading higher in after-market hours. The stock remains near the lower end of its one-month trading range.

2026. g. 30. jūl. 23:02 UTC

News

CRISPR Therapeutics shares are lower in after-market hours amid broader market weakness, despite analysts projecting revenue growth and a price target of $83.53.

2026. g. 29. jūl. 22:01 UTC

CRISPR Therapeutics AG shares are lower in after-market trading amid broader market declines driven by geopolitical tensions and caution ahead of the Fed's interest rate decision.

2026. g. 28. jūl. 23:01 UTC

Correlated Moves

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting broader market trends and a decline in the Russell 2000 Index.

2026. g. 27. jūl. 19:07 UTC

CRISPR Therapeutics AG shares are higher today, gaining since Friday's close. The stock peaked earlier in the session before pulling back.

2026. g. 23. jūl. 10:36 UTC

CRISPR Therapeutics AG shares are roughly flat in pre-market hours, with no specific company news identified. The stock remains near the lower end of its trading range.

2026. g. 22. jūl. 23:06 UTC

CRISPR Therapeutics AG shares are trading higher in after-market hours, though they remain below their 20-day moving average and near the lower end of their one-month range.

2026. g. 21. jūl. 19:26 UTC

News

Correlated Moves

CRISPR Therapeutics AG shares are higher today, buoyed by a strong gene-editing pipeline and positive analyst sentiment regarding its lead asset, CASGEVY.

2026. g. 20. jūl. 23:22 UTC

CRISPR Therapeutics AG is trading higher in after-market hours, despite broader market declines linked to rising treasury yields. No specific news was identified.

Salīdzinājums

Cenas izmaiņa

CRISPR Therapeutics AG Prognoze

Cenas mērķis

By TipRanks

50.21% augšup

Prognoze 12 mēnešiem

Vidējais 74.46 USD 50.21%

Augstākais 110 USD

Zemākais 45 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CRISPR Therapeutics AG — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

14 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 14 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CRISPR Therapeutics AG — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

67 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.